Aggredyne closes $3 million Series A convertible preferred stock financing Aggredyne.

Related StoriesNew medical chemistry analyzer launched by EKF at Medica 2015Transitioning infrared imaging into medical use: an interview with Dr Matthew BakerNew generation of RNAscope products for RNA-biomarker analysis in FFPE cells releasedThe technology was developed by researchers associated with the Utah Artificial Center Institute and originally certified from Brigham Young University to Thrombodyne, Inc. In Salt Lake City. Aggredyne has now acquired the worldwide, exclusive rights to the patents and technology, which had been licensed to ThromboVision previously, Inc. ‘We believe this state-of-the-art technology is so important to patients that people really needed to discover a way to make it open to the medical community,’ stated Chairman & CEO Edward R.The comparative effectiveness of FIT and colonoscopy for preventing death from colorectal cancer will be assessed at the completion of this 10-year trial.

ADA’s 2011 food and nutrition conference to be held in NORTH PARK The world’s largest annual meeting of food and nutrition professionals, the American Dietetic Association’s 2011 Food & Nutrition Conference & Expo, will be held September 24 to 27 in San Diego, Calif. FNCE attracts more than 10,000 registered dietitians, nutrition technology researchers, policy makers, health-care providers and market leaders for four days of cutting-edge nutrition research study and educational presentations, lectures, debates, panel discussions and culinary demonstrations, along with an increase of than 350 meals and nutrition-related exhibitors.